Shopping Cart

Your shopping cart is currently empty

Zomiradomide

Name: Zomiradomide
Brand: TargetMol
SKU: T75136
Price: 158 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T75136Cas No. 2655656-99-6

Alias KT-413, KT413, IRAK degrader-1

Zomiradomide is a PROTAC degradation agent targeting IRAK4, with oral bioavailability, and can also degrade Ikaros (IKZF1) and Aiolos (IKZF3), thereby inhibiting the NF-κB signalling pathway and activating the type I interferon signalling pathway, exhibiting anticancer activity against B-cell lymphoma.

Zomiradomide

Copy Product Info

🥰Excellent

Purity: 98.41%

Catalog No. T75136Alias KT-413, KT413, IRAK degrader-1Cas No. 2655656-99-6

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$158	In Stock	In Stock
5 mg	$283	In Stock	In Stock
10 mg	$425	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:98.41%

Appearance:Solid

Color:Yellow

Resource Download

COA HNMR LCMS

Product Introduction

Bioactivity

Description	Zomiradomide is a PROTAC degradation agent targeting IRAK4, with oral bioavailability, and can also degrade Ikaros (IKZF1) and Aiolos (IKZF3), thereby inhibiting the NF-κB signalling pathway and activating the type I interferon signalling pathway, exhibiting anticancer activity against B-cell lymphoma.
In vitro	Method: The diffuse large B-cell lymphoma (DLBCL) cell line OCI-Ly10 carrying the Myd88 L265P mutation was treated with various concentrations of Zomiradomide to assess its antiproliferative effect and determine the IC₅₀ value. Result: Zomiradomide effectively inhibited the proliferation of OCI-Ly10 cells, with an IC₅₀ of 11 nM. [2]
In vivo	Method: In OCI-Ly10 xenograft mouse models, Zomiradomide was administered orally at doses of 3–30 mg/kg once daily for 3 consecutive days to evaluate its antitumor effect. Result: Zomiradomide significantly inhibited tumor growth. [2]
Synonyms	KT-413, KT413, IRAK degrader-1

Chemical Properties

Molecular Weight	871.97
Formula	C₄₅H₄₈F₃N₇O₆S
Cas No.	2655656-99-6
Smiles	C(N1CC2(C1)CC(CCNC3=C4C(C(=O)N(C4=O)C5C(=O)NC(=O)CC5)=CC=C3)C2)[C@H]6CC[C@@H](CC6)C=7SC=8C(N7)=CC(C(C)(C)O)=C(NC(=O)C=9N=C(C(F)(F)F)C=CC9)C8

Storage & Solubility Information

Storage

store at low temperature | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 150 mg/mL (172.02 mM), Sonication is recommended.

In Vivo Formulation

2% DMSO+40% PEG300+5% Tween 80+53% Saline: 3 mg/mL (3.44 mM)

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.1468 mL	5.7341 mL	11.4683 mL	57.3414 mL
5 mM	0.2294 mL	1.1468 mL	2.2937 mL	11.4683 mL
10 mM	0.1147 mL	0.5734 mL	1.1468 mL	5.7341 mL
20 mM	0.0573 mL	0.2867 mL	0.5734 mL	2.8671 mL
50 mM	0.0229 mL	0.1147 mL	0.2294 mL	1.1468 mL
100 mM	0.0115 mL	0.0573 mL	0.1147 mL	0.5734 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Zomiradomide

Zomiradomide

Featured Recommendations

Batch Information

Resource Download

Product Introduction

Calculator

In Vivo Formulation Calculator (Clear solution)

Dose Conversion

Tech Support